As of Feb 21
| -0.07 / -1.38%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 6.75, with a high estimate of 11.00 and a low estimate of 4.00. The median estimate represents a +35.27% increase from the last price of 4.99.
The current consensus among 9 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.